1 week ago
India Tightens Cough Medicine Rules for Children Under Four
The Government of India has added a new safety rule for some medicines used for coughs, colds and blocked noses.
These medicines contain chlorpheniramine maleate and phenylephrine hydrochloride.
Children younger than four must not use these combinations.
This does not mean that every cough syrup has been banned for young children.
The government says the combinations may be risky and that safer alternatives are available.
Parents should check the ingredients instead of relying only on a brand name.
Many coughs are caused by viruses and can get better without cough medicine.
A child with breathing trouble, high fever, poor feeding, unusual sleepiness or dehydration should be seen by a doctor.
Parents should ask a qualified medical professional before giving cough or cold medicine.
The Government of India has restricted all fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four.
Manufacturers must place a prominent under-four warning on labels, package inserts and promotional materials.
The August 2026 action expands an April 2025 restriction covering certain formulations with the same ingredients.
Earlier measures included advisories for children under two, a ban on Almond Kit syrup in Tamil Nadu, and prescription requirements for syrup medicines.
Health guidance says many childhood coughs resolve without specific medicines, while products should be used only with appropriate medical advice.
- Who
- The Government of India, following recommendations from an expert committee and the Drugs Technical Advisory Board, issued the restriction.
- What
- It restricted the manufacture, sale and distribution of fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four.
- Where
- India.
- When
- The latest notification was issued in August 2026, following earlier actions in April and October 2025 and January and June 2026.
- Why
- The government cited potential risks for young children and the availability of safer alternatives; the broader scrutiny also followed deaths linked to contaminated cough syrups.
Key facts
- Affected medicines
- Fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride.
- Age restriction
- The combinations must not be used in children below four years.
- Required warning
- Manufacturers must display the age-specific warning on labels, package inserts and promotional materials.
- Earlier restriction
- Certain formulations containing the same ingredients were restricted in April 2025.
- Contaminated medicines
- The World Health Organization identified Coldrif, Respifresh TR and ReLife after diethylene glycol was detected.
- Other 2026 measure
- In June 2026, syrup medicines lost their earlier Schedule K exemption and became subject to regulated dispensing through prescriptions.
Sources
Related news
India Extends Restrictions on Two-Ingredient Medicines for Under-Four Children
Gujarat pharma firm partners held for illegal codeine cough syrup sale
India Tightens Sale Rules for Four CNS Drugs
Gujarat FDCA seizes fake hypertension tablets, restricts suspect medicines
Bombay High Court Rebukes FDA, Cipla Licence Order Withdrawn
Bombay HC rebukes Maharashtra FDA over Cadila drug sale halt
Haryana Bans High-Dose Nimesulide Oral Formulations
India Bans High-Dose Nimesulide Oral Medications
India to Restrict Unlicensed Cough Syrup Sales in Villages
